12.30-12.45 An evaluation of ophthalmic photographic diabetic review (OPDR) with two fields digital photography for diabetic maculopathy (M1) and 4 year follow-up.
H. Fellows, M. Shah, A. Hamid, L. Quant, M. Clarke, P.M. Dodson

12.45-1.00 Clinical and demographic features of patients with diabetic macular oedema.
F. Afshar, D. Baumgardt, C. Bailey

1.00 Best poster prize ceremony and closing remarks
Massimo Porta

TIMING
The meeting will be on 23th, 24th and 25th May 2013.

LOCATION
The meeting venue is the World Trade Center Barcelona (WTCB)
Moll de Barcelona s/n. Edificio Este
08039 Barcelona, Spain

Getting to the WTCB
The WTCB can be reached easily by public transport.
Bus 20, 21, 36, 64, 94, 120, N0, N6.
Metro lines 2 (Paral·lel) and 3 (Drassanes)

GALA DINNER
The Gala Dinner of the 23rd Meeting EASDec will take place in Port Vell (WTCB) on Friday 24th May at 7,30 for 8 pm.

MAIN SPONSORS:

Session 5
Roundtable 2: Fenofibrate in Diabetic Eye Disease
Chairs: Massimo Porta and Peter Scanlon
9.00-9.15 Simon Harding: Evidence from clinical trials
9.15-9.35 Rafael Simo: Potential mechanisms
9.35-9.50 Paul Dodson: Implications in clinical practice
9.50-10.00 Discussion

Session 6:
New Insights for Treatment of Diabetic Retinopathy
Chairs: Cristina Hernández and Eduard Malena
10.00-10.15 Effect of fenofibrate on retinal neurodegeneration in DB/DB mice.
L. Corraliza, P. Bogdanov, A.R. Rodrigues-Carvalho, J. García-Arumí, C. Hernández, R. Simo
10.15-10.30 Beneficial effects of somatostatin in cellular viability of retinal cells and retinal explants under diabetic conditions: possible role of protein tyrosine phosphatase 1B, Ana I Arroba, Deborah J Burks, Cristina Hernández-Pascual, Rafael Simo and Angela M Valverde.
10.30-10.45 The neuroprotective drugs somatostatin and brimonidine do not show adverse effects on human retinal pericytes.
T. Lopatina, E. Beltramo, M. Porta
10.45-11.00 Novel nopeptide superoxide dismutase mimetics attenuate hydrogen peroxide-induced damage to retinal ganglion cells and human retinal pericytes.
11.00-11.15 A shift in the balance of VEGF and CTGF by bevacizumab causes the angi-fibrotic switch in proliferative diabetic retinopathy.
11.15-11.45 Coffee

Session 7
The Diabetic Eye
Chairs: Elizabeth Agardh and Luis Arias
11.45-12.00 Estimating the interval preceding diagnosis of type 2 diabetes from the time-course of retinopathy prevalence.
M. Porta, G. Curletto, E. Coppo, A. Raviolo, M. Almani, P. Dalmasso
12.00-12.15 Baseline predictors of 3-year responses to ranibizumab and laser photocoagulation therapy in patients with visual impairment due to diabetic macular oedema.
V. Chung, P. Mitchell
12.15-12.30 Patient-reported visual function in diabetic macular oedema: 36-month results from the RESTORE extension study.

12.30-12.45 An evaluation of ophthalmic photographic diabetic review (OPDR) with two fields digital photography for diabetic maculopathy (M1) and 4 year follow-up.
H. Fellows, M. Shah, A. Hamid, L. Quant, M. Clarke, P.M. Dodson

12.45-1.00 Clinical and demographic features of patients with diabetic macular oedema.
F. Afshar, D. Baumgardt, C. Bailey

1.00 Best poster prize ceremony and closing remarks
Massimo Porta

TIMING
The meeting will be on 23th, 24th and 25th May 2013.

LOCATION
The meeting venue is the World Trade Center Barcelona (WTCB)
Moll de Barcelona s/n. Edificio Este
08039 Barcelona, Spain

Getting to the WTCB
The WTCB can be reached easily by public transport.
Bus 20, 21, 36, 64, 94, 120, N0, N6.
Metro lines 2 (Paral·lel) and 3 (Drassanes)

GALA DINNER
The Gala Dinner of the 23rd Meeting EASDec will take place in Port Vell (WTCB) on Friday 24th May at 7,30 for 8 pm.

MAIN SPONSORS:
Welcome

On behalf of the Local Organizing Committee, I am delighted to welcome you to the EASDec Annual Meeting 2013 in Barcelona. In this our 23rd Meeting we will present what we believe to be exciting new findings in both clinical and basic research into diabetic retinopathy and other diabetic eye associated diseases. In addition, it provides a good opportunity for us to exchange news and opinions, and to find out other research developments. We hope you will enjoy your stay in Barcelona and find sufficient time to experience the Mediterranean atmosphere of our city.

BOARD OF THE EASDec

President: Massimo Porta
Vice-President: Simon Harding
Secretary: Tunde Peto
Treasurer: Rafael Simó

EASDec 2013 Programme

The entire conference, including the Opening ceremony and the dinner will be held at the WTCB.

23rd May 2013, Thursday

"Satellite Symposium": Spanish Society of Retina and Vitreous (SERV) (Supported by Novartis Spain)
4.00 - 7.00 New perspectives in the diagnostic and treatment of Diabetic Macular Oedema
Chairs: José García-Arumi and Rafael Simó
The official programme of EASDec starts with:
7:00 Opening ceremony followed by refreshments

24th May 2013, Friday

8.30 - 9.00 Registration
9.00 Introduction and welcome Rafael Simó

Session 1

New Perspectives in the Treatment of Diabetic Macular Oedema
Chairs: José García-Arumi and Gabrielle E. Lang
11.00-11.20 In memoriam Ann Katrin Sjolie presented by Massimo Porta
11.20-11.45 Coffee/tea, exhibitions

Session 2

Laboratory and Clinical Biomarkers of Diabetic Retinopathy
Chair: Rein M. Schlingemann and Jose Cunha-Vaz
11.45-12.00 Aqueous humor biomarkers of retina microglia activation in diabetic patients. S. Vujosevic, M. Berton, S. Bini, A. Micera, G. Esposito, O. Kotsafti, E. Midena
12.15-12.30 Microaneurysm turnover predicts risk of development of clinically significant diabetic macular oedema. I. Ribiero, S. Cunha-Vaz
12.30-12.45 Microaneurysm count as a predictor of progression of retinopathy in patients with type 1 diabetes? M. L. Rasmussen, B. Pedersen, T. Peto, J. Grauslund
Patterns of progression in diabetic retinopathy correlation between phenotypes and genotypes
S. Nunes, C. Lobo, I. Pires, M. J. Simões, C. Faro, J. Cunha-Vaz
12.45-1.00 Obstructive sleep apnea is associated with sight threatening retinopathy and predicts the development of proliferative and proliferative retinopathy in patients with type 2 diabetes. A. Tahraní, P. Dodson, A. Ali, Q. Altaf, H. Wharton, N. T. Raymond, M. J. Simões
1.00-1.15 Automated detection of leakage sites in fundus fluorescein angiography for diabetic maculopathy. W. M. Wiersinga, A. Tahrani, P. Dodson, A. Ali, Q. Altaf, H. Wharton
1.15-1.30 Lunch and Poster Session

Session 3

Posters Session
Moderators: Tunde Peto and Anna Boixadura

Screening
- Diabetic retinopathy screening at a UK district general hospital. F. Blair, S. Shadquat
- Is it safe to increase diabetic retinopathy screening interval in patients with no background diabetic retinopathy? H. Chambers, S.B. Bahu, H.W. Wharton, P.M.D. Dodson, J.M.G. Gibson
- Epiretinal membrane in diabetic retinopathy screening. N. Bilhku, A.D. Wright, I. Aarnomaki, R.O. Schlingemann, P.M. Dodson
- Is arbitration of all abnormal grades valuable in retinopathy grading quality assurance? L. Quast, A.P. Mills, A. Hamid, H. Wharton, M. Clarke, P.M. Dodson
- Evaluation of automated image analysis software for the detection of diabetic retinopathy to reduce the ophthalmologist workload. E. Soto-Pedre, A. Navea, J. Morales, S. Millan, M.C. Hernandez-Ortega, P. Perez, M.C. Desco
- Review of change in referral rates to hospital eye services from a population based diabetic screening service during the initial six years of service delivery. M. Morgan, M. Murphy
- Are diabetic retinopathy virtual clinics safe? O. Giasan, J. Myerscroft, C. James, Y. Osoba
- Relationship between time from diagnosis of diabetes to grading and grading outcome. S. Aldington, L. Stratton, M. Hirst, H.F. Scanlon
- Accuracy of sliscopie referrals from diabetic retinopathy screening. T. Peto, K. Balaskas, R. Cuertas
- J. Stuart, L. Stratton, A. Lindemeyer, P.H. Scanlon

Basic Research
- Role of vascular endothelium growth factor (VEGF) and renin-angiotension systems in pathogenesis diabetic retinopathy. D. Lipatov, J.E. Bautina, M.V. Shestakova, A.G. Kuzmin, T.A. Chistjakov, S. Vujosevic
- VEGF levels in plasma in relation to platelet activation, glycermic control and microvascular complications in type 1 diabetes mellitus. R. Schlingemann, C.J.F. Van Noorden, J.C.M. Meijers, W.M. Wiersinga
- Is arbitration of all abnormal grades valuable in retinopathy grading quality assurance? L. Quast, A.P. Mills, A. Hamid, H. Wharton, M. Clarke, P.M. Dodson
- Automated detection of leakage sites in fundus fluorescein angiography for diabetic maculopathy. M. L. Rasmussen, T. Peto, J. Grauslund

Prevalence of Diabetic Retinopathy
- RELIGHT- ranibizumab treatment of diabetic macular edema with delayed and minimal treatment after initial treatment. I. Pearce, The RELIGHT Study group

Epidemiology
- Sixteen-year incidence of diabetic retinopathy and proliferative diabetic retinopathy in a nationwide cohort of young Danish type 1 diabetic patients. R. B. Pedersen, M.L. Rasmussen, T. Peto, J. Grauslund
- Non-Swedish origin may be a risk factor for diabetic retinopathy at diagnosis in Scania, Sweden, in 2008-2012. C. Gustavsson, M. Dorkhan, L. Groop
- Staging of diabetic retinopathy upon initial presentation in Saudi Arabia. K.M. Gandour, S. Wahbeh, I.A. Alhahlbi, A.K. Raafatman
- The effects of combined therapy with metformin and sulfonylurea on clinical characteristics of metabolic syndrome in type 2 diabetes mellitus. M. Carman, S. Carman, M. Keci

Session 4

Pathophysiology of Diabetic Eye Disease
Chairs: Anna Boixadura and Tozser J.
14.00-14.30 In Memoriam Anne Katrin Sjolie presented by Massimo Porta
14.30-14.45 Eva Kohner lecture
14.45-5.30 Annual General Meeting
Moderator: Tunde Peto
Gala dinner: 7.30 for 8.00 in Port Vell (WTCB)